These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 27084692)

  • 1. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
    Lam RW; Milev R; Rotzinger S; Andreazza AC; Blier P; Brenner C; Daskalakis ZJ; Dharsee M; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Geraci J; Giacobbe P; Feilotter HE; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; Liotti M; MacQueen GM; McAndrews MP; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Salomons TV; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Kennedy SH;
    BMC Psychiatry; 2016 Apr; 16():105. PubMed ID: 27084692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
    Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
    J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
    Chakrabarty T; McInerney SJ; Torres IJ; Frey BN; Milev RV; Müller DJ; Rotzinger S; Kennedy SH; Lam RW;
    CNS Drugs; 2021 Mar; 35(3):291-304. PubMed ID: 33683582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
    Trials; 2011 Jan; 12():4. PubMed ID: 21208417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report.
    Phaterpekar T; Nunez JJ; Morton E; Liu YS; Cao B; Frey BN; Milev RV; Müller DJ; Rotzinger S; Soares CN; Taylor VH; Uher R; Kennedy SH; Lam RW
    J Clin Psychiatry; 2023 Nov; 85(1):. PubMed ID: 37967350
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
    JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.
    Trivedi MH; McGrath PJ; Fava M; Parsey RV; Kurian BT; Phillips ML; Oquendo MA; Bruder G; Pizzagalli D; Toups M; Cooper C; Adams P; Weyandt S; Morris DW; Grannemann BD; Ogden RT; Buckner R; McInnis M; Kraemer HC; Petkova E; Carmody TJ; Weissman MM
    J Psychiatr Res; 2016 Jul; 78():11-23. PubMed ID: 27038550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial.
    Dunlop BW; Binder EB; Cubells JF; Goodman MM; Kelley ME; Kinkead B; Kutner M; Nemeroff CB; Newport DJ; Owens MJ; Pace TW; Ritchie JC; Rivera VA; Westen D; Craighead WE; Mayberg HS
    Trials; 2012 Jul; 13():106. PubMed ID: 22776534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
    Grieve SM; Korgaonkar MS; Gordon E; Williams LM; Rush AJ
    J Clin Psychiatry; 2016 Apr; 77(4):e436-43. PubMed ID: 27137427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.
    Cook IA; Hunter AM; Gilmer WS; Iosifescu DV; Zisook S; Burgoyne KS; Howland RH; Trivedi MH; Jain R; Greenwald S; Leuchter AF
    J Clin Psychiatry; 2013 Jan; 74(1):51-6. PubMed ID: 23419226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.
    Phillips JL; Jaworska N; Kamler E; Bhat V; Blier J; Foster JA; Hassel S; Ho K; McMurray L; Milev R; Moazamigoudarzi Z; Placenza FM; Richard-Devantoy S; Rotzinger S; Turecki G; Vazquez GH; Kennedy SH; Blier P;
    BMC Psychiatry; 2020 Jun; 20(1):268. PubMed ID: 32487236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
    Dunlop K; Rizvi SJ; Kennedy SH; Hassel S; Strother SC; Harris JK; Zamyadi M; Arnott SR; Davis AD; Mansouri F; Schulze L; Ceniti AK; Lam RW; Milev R; Rotzinger S; Foster JA; Frey BN; Parikh SV; Soares CN; Uher R; Turecki G; MacQueen GM; Downar J
    Neuropsychopharmacology; 2020 Jul; 45(8):1390-1397. PubMed ID: 32349119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.
    Morton E; Bhat V; Giacobbe P; Lou W; Michalak EE; McInerney S; Chakrabarty T; Frey BN; Milev RV; Müller DJ; Parikh SV; Rotzinger S; Kennedy SH; Lam RW;
    CNS Drugs; 2021 Apr; 35(4):439-450. PubMed ID: 33860922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report.
    Suh JS; Minuzzi L; Raamana PR; Davis A; Hall GB; Harris J; Hassel S; Zamyadi M; Arnott SR; Alders GL; Sassi RB; Milev R; Lam RW; MacQueen GM; Strother SC; Kennedy SH; Frey BN
    Neuroimage Clin; 2020; 25():102178. PubMed ID: 32036277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial.
    Grieve SM; Korgaonkar MS; Etkin A; Harris A; Koslow SH; Wisniewski S; Schatzberg AF; Nemeroff CB; Gordon E; Williams LM
    Trials; 2013 Jul; 14():224. PubMed ID: 23866851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.
    Baskaran A; Farzan F; Milev R; Brenner CA; Alturi S; Pat McAndrews M; Blier P; Evans K; Foster JA; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Strother SC; Turecki G; Kennedy SH;
    J Affect Disord; 2018 Feb; 227():542-549. PubMed ID: 29169123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of
    Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
    Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder.
    Tadić A; Wagner S; Gorbulev S; Dahmen N; Hiemke C; Braus DF; Lieb K
    BMC Psychiatry; 2011 Jan; 11():16. PubMed ID: 21269443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1.
    Nunez JJ; Nguyen TT; Zhou Y; Cao B; Ng RT; Chen J; Frey BN; Milev R; Müller DJ; Rotzinger S; Soares CN; Uher R; Kennedy SH; Lam RW
    PLoS One; 2021; 16(6):e0253023. PubMed ID: 34181661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Hack LM; Tozzi L; Zenteno S; Olmsted AM; Hilton R; Jubeir J; Korgaonkar MS; Schatzberg AF; Yesavage JA; O'Hara R; Williams LM
    JAMA Netw Open; 2023 Jun; 6(6):e2318411. PubMed ID: 37318808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.